TY - JOUR T1 - Pre-diagnostic plasma metabolomics and the risk of exfoliation glaucoma JF - medRxiv DO - 10.1101/2021.08.02.21261514 SP - 2021.08.02.21261514 AU - Jae H. Kang AU - Oana Zeleznik AU - Lisa Frueh AU - Jessica Lasky-Su AU - A. Heather Eliassen AU - Clary Clish AU - Bernard A. Rosner AU - Louis R. Pasquale AU - Janey L. Wiggs Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/05/2021.08.02.21261514.abstract N2 - Objective To identify pre-diagnostic plasma metabolomic biomarkers associated with risk of exfoliation glaucoma (XFG).Methods We conducted a metabolomic study using a 1:1 matched nested case-control study design within the Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS). Participants provided blood samples in 1989-’90 (NHS) and 1993-’95 (HPFS); we identified 205 participants who newly developed XFG during follow-up to 2018 (average time to diagnosis from blood draw =11.8 years); XFG was confirmed with medical record review. We profiled plasma metabolites using liquid chromatography- mass spectrometry and identified 379 known metabolites that passed quality control checks. Metabolites were transformed using probit scores for normality. We used multivariable-adjusted logistic regression adjusting for matching factors (such as age, residential latitude, season and time of blood draw), glaucoma family history and other covariates. Metabolite Set Enrichment Analysis was used to identify metabolite classes associated with risk of XFG. Number of effective tests (NEF) and False Discovery Rate (FDR) were used to adjust for multiple comparisons.Results Mean age of cases (n=205) at diagnosis was 71 years; 84% were women and >99% were Caucasian; matched controls (n=205) all reported eye exams as of the matched cases’ index date. A total of 33 metabolites were nominally significantly associated with XFG risk (p<0.05) and 4 metabolite classes were significantly associated (FDR<0.05). Overall, adverse associations were observed for the classes of lysophosphatidylcholines (FDR=0.02) and phosphatidylethanolamine plasmalogens (FDR=0.004). Inverse associations were observed for triglycerides (FDR<0.001) and steroid and steroid derivatives (FDR=0.03); in particular, the multivariable-adjusted odds ratio for XFG risk associated with each 1 standard deviation increase in plasma cortisone levels was 0.49 (95% CI=0.32-0.74; NEF=0.05). Results did not differ materially by time between blood draw and diagnosis, latitude of residence (< or ≥41°N latitude), age (< or ≥60 years), sex or glaucoma family history.Conclusions Four broad classes of metabolites (including steroids such as cortisone and 3 lipid classes) in pre-diagnostic plasma collected almost a decade before diagnosis were associated with XFG risk; these results should be confirmed in future studies.Competing Interest StatementDr. Pasquale is a consultant to Eyenovia, Twenty twenty and Skye Biosciences. Dr. Wiggs is a consultant to Allergan, Avellino, Editas, Maze, Regenxbio and has received research support from Aerpio.Funding StatementThis work was supported by NEI R01 EY020928, R01 EY015473 (LRP), NCI UM1 CA186107, U01 CA167552, and an unrestricted challenge grant to Icahn School of Medicine at Mount Sinai, Department of Ophthalmology from Research to Prevent Blindness (LRP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Brigham and Women's Hospital IRB protocol: Gene-Environment Interactions in Glaucoma (2004-P-002701)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInformation including the procedures to obtain and access data from the Nurses' Health Studies and Health Professionals Follow-up Study is described at https://www.nurseshealthstudy.org/researchers (contact email: nhsaccess@channing.harvard.edu) and https://sites.sph.harvard.edu/hpfs/for-collaborators/ ER -